DioGenix, Inc., a Gaithersburg, MD-based developer of novel molecular tests, raised $3.2m in financing.
Backers included new individual and returning investors including life sciences fund Nerveda, LLC.
The financing follows recent interim results from a prospective clinical trial of DioGenix’ MSPrecise®, a sequencing assay which continues to show that it can accurately identify patients with multiple sclerosis (MS) at first clinical presentation.
The company intends to use the funds to complete a prospective clinical diagnostic trial which should validate the performance of MSPrecise in a population of patients being evaluated for multiple sclerosis (MS) and a variety of other neurological diseases.
Led by Larry Tiffany, President and CEO, DioGenix has also established a new central laboratory that will serve as the basis for its future commercialization of MSPrecise upon CLIA licensure and expanded its licensing arrangement with the University of Texas Southwestern Medical Center (UTSW) to provide exclusivity to core technology related to MSPrecise for MS and other neurological diseases.